688363 Bloomage Biotechnology Corporation Limited
- 58.75
- +0.57+0.98%
Bloomage Biotechnology Corporation Limited News
Huaxi Biotech (688363): Management changes have dragged down 23 years of performance, waiting for an inflection point in business
Huaxi Biotech (688363) Comment: Revenue is expected to drop by about 4% in '23, and management changes are being upgraded and implemented throughout the year
Huaxi Biotech (688363) 23Q3 Quarterly Report Review: Q3 Performance Is Under Short-Term Pressure, Still Waiting for an Inflection Point in Management
Huaxi Biotech (688363): Skincare business strategy adjustments and sales expense ratio optimized
Research Report Nuggets | Caixin Securities: Maintaining Huaxi Biotech's “buy” rating, the logic of rising volume and prices in the medical and aesthetic business sector is still being interpreted
Huaxi Biotech (688363): It is expected that the cosmetics business is under pressure in the short term, raw materials will be steady, and medical aesthetics will maintain relatively rapid growth
Huaxi Biotech (688363): Effective skincare continues to slow, expect organizational changes, results, and performance recovery
Huaxi Biotech (688363): The cosmetics business may continue to put pressure on the medical and aesthetic business or grow further
Huaxi Biotech (688363) 2023 Third Quarter Report Review: Skincare Business Adjustments, Changes, and Medical Aesthetic Business Development Is Booming
Deep* Company* Huaxi Biotech (688363): Q3 revenue declined, skincare business deepened reforms
Research Report Nuggets | Wanlian Securities: Huaxi Biotech's Q3 performance is under pressure in the short term, waiting for results to show after the reform
Huaxi Biotech (688363) 2023 Three Quarter Report Review: Phased Adjustment of Functional Skincare to Optimize Operations and Plan Ahead for the Rain
Huaxi Biotech (688363) 2023 Third Quarter Report Review: Q3 Performance Continues Under Pressure, Multiple Cosmetics Brands Are Intensively Promoting
Huaxi Biotech (688363): Short-term strategic adjustments affect performance and expect improvements in functional skincare management
Huaxi Biotech (688363): Internal adjustments are dragging down the cosmetics business and looking forward to the growth of multiple businesses
Huaxi Biotech (688363): Q3 is under pressure due to external influences during the adjustment period and is expected to be Nirvana in '24
Huaxi Biotech (688363) 2023 Third Quarter Report Review: Cosmetics Business Strategy Adjustment, Sales Expense Ratio Optimization Year Over Year
Huaxi Biotech (688363): 23Q3 performance under pressure, cost optimization, and R&D projects go hand in hand
Huaxi Biotech (688363): Continued adjustment of cosmetics business, deepening focus on the steady upward pace of sales
Huaxi Biotech (688363): Q3 skincare products are under pressure, expecting the effects of changes to drive business improvements
Analysis
Price Target
No Data
